Arontier

Arontier Co, Ltd.(founded in 2017) is an AI-driven drug discovery company specializing in structure-based therapeutic design. Our mission is to accelerate the discovery of novel medicines by combining AI, structural biology, chemistry, and translational medicine. Arontier has developed an end-to-end drug discovery platform that integrates small molecules, peptides, proteins, antibodies, and synthetic antigens for vaccines. By partnering with pharmaceutical companies, major hospitals, and academic research institutes, we advance pipelines across oncology, immunology, and infectious diseases. Backed by investors and multiple national R&D grants, Arontier is committed to delivering faster, more precise, and cost-effective drug discovery solutions.